Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1063144
Abstract: Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration. The UK was an early… read more here.
Keywords: benefits switching; healthcare providers; daratumumab; intravenous subcutaneous ... See more keywords